Across TCGA pan-cancer cohorts, ZBTB9 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ZBTB9 data layer compared with 20 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ZBTB9 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ZBTB9 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

PDAC, HNSC, and UCEC are the cancer types where ZBTB9 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	All	0.266	0.842	<.001	33	view →
HNSC	DFS	Tertile	All	0.680	0.979	.010	14	view →
UCEC	DFS	Median	All	1.000	0.936	.023	4	view →
LSCC	DFS	Median	All	0.285	0.852	.012	2	view →
CCRCC	DFS	Median	II,III,IV	0.805	1.000	.033	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: ZBTB9 tumor-vs-normal RNA expression · all ZBTB9 data types